T-E Meds, Inc. is a subsidiary company of T-E Pharma Holding which focuses on antibody-drug conjugates (ADCs) and antibody-radionuclide conjugates (ARCs). Its proprietary technology platforms enable designs of “T-E” drug molecules, in which the targeting moiety (T) directs the drug molecule to specific cells or tissues, and the effector moiety (E) performs the intended therapeutic functions. The ADCs and ARCs are based on innovative “Multi-Arm Linker” technology and proprietary conjugation methods. Using an enzyme-free click reaction, site-specific conjugation ADC/ARC with high DAR can be produced with high reaction yield and high purity, which could be considered the best-in-class bioconjugation technology platform. Three drug candidates in preclinical development are designed for treating various cancer diseases and IND filings for two of them are scheduled between 2024-2025.